Özdemir Enver, Çiçek Tarık, Kaya Mehmet Onur
Department of Urology, Fırat University Hospital, Elazığ, Turkey.
Urol J. 2012 Summer;9(3):568-73.
To investigate the relationship between serum level of YKL-40 and Gleason score, grade and stage of the disease, and for the first time, with tumor burden in patients with prostate cancer (PCa).
Serum levels of YKL-40 and prostate-specific antigen were measured in 34 men (mean age: 66 years) with newly diagnosed and untreated PCa, in 34 men (mean age: 65 years) with biopsy proven benign prostatic hyperplasia, and in 29 healthy young men (mean age: 24 years).
Serum YKL-40 concentration in men with PCa and benign prostatic hyperplasia, and in controls were 165.67 ± 107.84 ng/mL, 137.38 ± 82.04 ng/mL, and 69.69 ± 18.46 ng/mL, respectively. Serum level of YKL-40 was correlated with tumor burden in 30.4% of the patients with PCa (P = .04). A cut-off serum YKL-40 value of 92.696 ng/mL produced 70.6% sensitivity and 93.1% specificity. Elevated serum level of YKL-40 was strongly associated only with metastatic stage of the PCa. No association was observed between elevated level of YKL-40 and Gleason score groups or Gleason grade.
Our results suggest that elevated serum level of YKL-40 may be a useful indicator of tumor burden and metastatic stage of PCa. Further studies are warranted to better elucidate the meaning of YKL-40 in tumor burden and invasiveness.
研究血清YKL-40水平与前列腺癌（PCa）患者的Gleason评分、疾病分级和分期之间的关系，并首次研究其与肿瘤负荷的关系。
检测34例新诊断且未接受治疗的PCa男性患者（平均年龄：66岁）、34例经活检证实为良性前列腺增生的男性患者（平均年龄：65岁）以及29例健康青年男性（平均年龄：24岁）的血清YKL-40和前列腺特异性抗原水平。
PCa患者、良性前列腺增生患者及对照组的血清YKL-40浓度分别为165.67±107.84 ng/mL、137.38±82.04 ng/mL和69.69±18.46 ng/mL。30.4%的PCa患者血清YKL-40水平与肿瘤负荷相关（P = .04）。血清YKL-40临界值为92.696 ng/mL时，灵敏度为70.6%，特异性为93.1%。血清YKL-40水平升高仅与PCa的转移期密切相关。未观察到YKL-40水平升高与Gleason评分组或Gleason分级之间存在关联。
我们的结果表明，血清YKL-40水平升高可能是PCa肿瘤负荷和转移期的有用指标。有必要进一步研究以更好地阐明YKL-40在肿瘤负荷和侵袭性方面的意义。
